Galderma
CLICK HERE if you are a Consumer
Roll Over for Important Safety Information
Metrogel: The one with the Enhanced Formulation for exceptional tolerability

  • In patient satisfaction questionnaire analysis, patients favored METROGEL® (metronidazole) Gel, 1% and 84.4% said that they were likely to use it in the future compared with 79.9% for azelaic acid 15% gel


  • Only 4.4% of patients experienced treatment-related adverse events which resolved quickly


  • Patients treated with METROGEL® 1% were significantly less bothered with side effects than patients using azelaic acid 15% gel


  • 74% of patients said they were not bothered at all by treatment side effects (vs. 52.7% for azelaic acid 15% gel)


  • After 3 weeks of treatment, patients treated with METROGEL® 1% experienced significantly lower incidences of burning and stinging than patients using azelaic acid 15% gel


  • There is low potential for hypopigmentation associated with the use of METROGEL® 1%


  • Adverse events reported and associated with metronidazole 1% gel treatment included conjunctivitis, abdominal pain, facial pain, hypoesthesia, rosacea flare and skin desquamation

HELP YOUR PATIENTS
 FIND A DERMATOLOGIST
(Enter the first 3 digits of your zip code)

IMPORTANT SAFETY INFORMATION

METROGEL® (metronidazole) Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. The most common adverse reactions that have been reported with the topical use of METROGEL® 1% are nasopharyngitis, upper respiratory tract infections and headaches, as well as dryness, scaling, itching, and stinging. Transient redness, metallic taste, tingling or numbness of extremities and nausea have also been reported with the topical use of metronidazole. METROGEL®1% therapy should be reevaluated if these symptoms occur. Caution should be used when prescribing metronidazole products for patients with blood dyscrasia, and patients using blood thinning agents such as coumarin or warfarin may experience prolonged prothrombin times. METROGEL® 1% is contraindicated in patients with a history of hypersensitivity to metronidazole or any other ingredient in the formulation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.